[
  {
    "ts": null,
    "headline": "Why Analysts Are Raising Targets as TTM Technologies Story Shifts on Strong Growth Signals",
    "summary": "TTM Technologies stock has seen its consensus analyst price target rise significantly from $62.75 to $75.50. This change signals increased optimism around the company’s future prospects. Analysts point to recent strong results and confident guidance as key drivers of this more positive outlook. Keep reading to discover how you can track ongoing shifts in the stock's story and ensure you are always informed about future updates. Stay updated as the Fair Value for TTM Technologies shifts by...",
    "url": "https://finnhub.io/api/news?id=c9264dbeb371203dc5fffab218cf989be9fea8efa3404cad71055547ce0afeab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762654369,
      "headline": "Why Analysts Are Raising Targets as TTM Technologies Story Shifts on Strong Growth Signals",
      "id": 137384679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "TTM Technologies stock has seen its consensus analyst price target rise significantly from $62.75 to $75.50. This change signals increased optimism around the company’s future prospects. Analysts point to recent strong results and confident guidance as key drivers of this more positive outlook. Keep reading to discover how you can track ongoing shifts in the stock's story and ensure you are always informed about future updates. Stay updated as the Fair Value for TTM Technologies shifts by...",
      "url": "https://finnhub.io/api/news?id=c9264dbeb371203dc5fffab218cf989be9fea8efa3404cad71055547ce0afeab"
    }
  },
  {
    "ts": null,
    "headline": "Looking at the Narrative for Medpace as Analyst Sentiment and Growth Outlook Shift",
    "summary": "Medpace Holdings has recently seen its consensus analyst price target rise from $456 to approximately $519. This reflects a higher estimated fair value as sentiment improves across the contract research and biotech sectors. This repricing comes amid growing optimism about industry recovery and Medpace's outlook, even as some uncertainties persist. Stay tuned to find out how you can stay informed as the story around Medpace Holdings continues to evolve. Stay updated as the Fair Value for...",
    "url": "https://finnhub.io/api/news?id=0c14a726968ef2a59e4e2ba44743342ab152835c255696bf91b77a1d9eb80ae2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762647680,
      "headline": "Looking at the Narrative for Medpace as Analyst Sentiment and Growth Outlook Shift",
      "id": 137384680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Medpace Holdings has recently seen its consensus analyst price target rise from $456 to approximately $519. This reflects a higher estimated fair value as sentiment improves across the contract research and biotech sectors. This repricing comes amid growing optimism about industry recovery and Medpace's outlook, even as some uncertainties persist. Stay tuned to find out how you can stay informed as the story around Medpace Holdings continues to evolve. Stay updated as the Fair Value for...",
      "url": "https://finnhub.io/api/news?id=0c14a726968ef2a59e4e2ba44743342ab152835c255696bf91b77a1d9eb80ae2"
    }
  }
]